Merck (MRK) on Solana

Merck has taken an equity stake in Evaxion A/S, a Danish AI-driven biotech, and licensed EVX-B3, the company's artificial intelligence-guided vaccine candidate, extending Merck's drug discovery approach into AI-powered immunology. Financial terms of the deal were not disclosed. The move marks a distinct expansion beyond Merck's existing mRNA oncology work — including its intismeran combination with KEYTRUDA, which posted Phase 3 wins in melanoma — into AI-designed preventive vaccine science.

The Evaxion partnership fits Merck's stated strategy of building more than 20 potential growth drivers to reduce reliance on KEYTRUDA ahead of its patent expiration. EVX-B3's progression through clinical trials, patient enrollment, and safety readouts will be the near-term milestones to watch as indicators of whether the AI vaccine bet translates into a meaningful pipeline asset.

Merck's personalized mRNA cancer vaccine, intismeran autogene, achieved statistically significant results in a Phase 3 trial when combined with flagship immunotherapy Keytruda, demonstrating effectiveness in preventing recurrence or metastasis in high-risk melanoma patients. The readout adds a fresh clinical catalyst to an already expanded pipeline — Merck has reportedly nearly tripled its late-phase pipeline since 2021, with commercial opportunities estimated to exceed $50 billion by the mid-2030s.

The clinical progress has contributed to MRK shares gaining roughly 40% year-to-date and nearly 79% over the past year, but the rally has sharpened a valuation debate among analysts. The consensus analyst fair value sits around $136.85, implying the stock trades roughly 9% above that level, while a DCF model cited by Simply Wall St places intrinsic value considerably higher at $232.91. Bears point to the looming Keytruda patent cliff and potential margin pressure from tariffs and drug pricing policy as risks that the current price may not fully discount.

Morgan Stanley upgraded Merck (MRK) to Overweight from Equal Weight and raised its price target to $179 from $116, implying roughly 17% upside from Wednesday's close. The upgrade came alongside the company's announcement of promising late-stage oncology trial results in partnership with Moderna, which lifted shares 13% — their best single-day gain since March 2009. Keytruda, Merck's flagship immunotherapy, generated more than $16 billion in first-half sales, and analysts noted that potential co-formulations of the drug could extend its commercial franchise beyond the upcoming 2028 patent expiration.

The analyst flagged several pipeline assets as key drivers of growth post-Keytruda: intismeran autogene and sac-TMT for oncology, and tulisokibart targeting inflammatory bowel disease. Morgan Stanley's view is that the breadth of Merck's pipeline, combined with Keytruda's sustained revenue base, gives the company multiple paths to offset the impact of biosimilar competition when exclusivity lapses.

President Trump signed an executive order on August 10, 2026 directing the administration to make individual measles, mumps, and rubella vaccines available as separate shots rather than the current combined formulation, citing unsubstantiated links to autism. The order also reorganizes the childhood immunization schedule and requires that vaccines be administered at separate medical visits. Merck, as the manufacturer of M-M-R II — the dominant licensed MMR vaccine in the United States — faces the prospect of demand disruption for its existing combined product should the order ever be implemented. Separately licensed single-antigen vaccines for measles, mumps, and rubella do not currently exist in the U.S. market, meaning Merck and any other manufacturers would face lengthy and expensive clinical trial programs to win individual FDA approvals before standalone products could be sold.

Experts and major medical groups including the American Academy of Pediatrics say the split is scientifically unwarranted and practically unlikely to materialize on a short timeline given the absence of approved products. The order carries no immediate force over state-level school vaccine mandates, which govern most immunization requirements. In the near term, the greater risk to Merck is not lost sales but reputational pressure on its core vaccine franchise and the added cost burden if regulators or policymakers eventually require development of disaggregated products. Public health officials also warn the policy could reduce vaccination adherence through added doctor visits at a time when measles cases in 2026 have already exceeded the full-year total for 2025.

Merck beat second-quarter 2026 estimates and raised its full-year revenue guidance to $66.3 billion–$67.3 billion, up from a prior range of $65.8 billion–$67 billion, driven by strong demand for newer drugs including Winrevair. The company has been actively expanding its pipeline to offset approaching generic competition for Januvia and Janumet later in 2026 and for blockbuster immunotherapy Keytruda in 2028.

At the same time, Merck cut its full-year adjusted EPS guidance sharply to $2.66–$2.76, down from prior guidance of $5.04–$5.16, primarily due to a $2.31-per-share one-time charge related to its acquisition of Terns Pharmaceuticals, which closed in May, plus roughly $0.12 per share to finance the deal and advance Terns's cancer drug candidate. The result is a mixed quarter: the underlying business is performing ahead of expectations on revenue, while the profit line reflects the near-term cost of Merck's acquisition-heavy strategy to build out its post-Keytruda portfolio.

Merck has signed royalty-free, non-exclusive licenses with seven generic manufacturers to produce its investigational once-monthly oral HIV prevention pill alimatravir across 129 low and middle-income countries — ahead of the drug completing Phase 3 trials. The early voluntary licensing approach, which targets high-burden regions including sub-Saharan Africa and Latin America, is designed to build supply chain capacity and enable rapid rollout if the drug clears regulatory approval. Partners such as Aurobindo Pharma are being positioned to pursue their own regulatory filings in covered markets.

The move marks a departure from the conventional approach of waiting until after approval to negotiate generic access deals, reflecting pressure on pharmaceutical companies to address HIV treatment gaps in resource-limited settings. With two ongoing Phase 3 trials under the EXPrESSIVE program, Merck has not yet announced regulatory filing timelines, but the pre-approval licensing infrastructure signals a commitment to broad access as a commercial and public health strategy alongside its existing HIV and oncology portfolio.

A discounted cash flow analysis of Merck (MRK) points to an intrinsic value of roughly $228 per share — implying the stock is about 43% undervalued relative to its current price near $125, based on trailing twelve-month free cash flow of $14 billion. On that measure alone, MRK looks notably cheap. But the earnings picture complicates the case: at 36x trailing P/E, Merck trades well above the pharmaceuticals industry average of 15.7x and above a peer-group average of 27.5x, with the implied fair P/E sitting at 36.3x — suggesting the multiple is already full. A broader six-factor valuation check returns a score of 3 out of 6, placing MRK squarely in "mixed zone" territory.

The divergence reflects genuine uncertainty about how much of Merck's future cash flow pipeline investors should credit to newer products versus franchises facing headwinds. Bulls point to a late-phase pipeline that has nearly tripled since 2021, with commercial opportunity potentially exceeding $50 billion by the mid-2030s anchored by Keytruda. Bears counter that the Inflation Reduction Act's drug-pricing provisions and broader global pricing pressure could erode revenue growth and compress margins across both the pipeline and flagship products. For MRK investors, the key variable is whether the company can convert its pipeline progress into earnings growth that justifies the current multiple — if it can, the FCF-based discount could look prescient; if margins slip, the P/E leaves little room for error.

Merck has expanded its clinical trial collaboration with Phanes Therapeutics to evaluate spevatamig alongside KEYTRUDA® (pembrolizumab) and chemotherapy as a first-line treatment for biliary tract cancer (BTC). The original collaboration, established in 2023, has now broadened to include BTC, a cancer with limited treatment options and significant unmet medical need.

Spevatamig is a first-in-class bispecific antibody targeting claudin 18.2 and CD47, classified as an innate immunity enhancer (I₂E) designed to activate macrophages and dendritic cells against tumors. The combination strategy pairs spevatamig's innate immune activation with KEYTRUDA's established checkpoint inhibition, aiming to improve outcomes in tumor types that typically resist immunotherapy alone. No financial terms were disclosed.

Merck (MRK) trades near $128 with a trailing twelve-month P/E of 35.3x, a figure that appears expensive at first glance. The picture shifts sharply when viewed against analyst consensus for 2027, where the forward P/E compresses to just 13.2x — a 63% discount to the trailing multiple. The gap is explained largely by management guidance for 2026 non-GAAP EPS of $5.04–$5.16, far above the $2.77 consensus estimate for the same year, and by projected revenue growing at roughly 3.3% annually, consistent with recent quarters.

The compressed forward multiple reflects market expectations that Merck's pipeline transformation will deliver. Management has described the portfolio as being reshaped by "initial launches of over 20 new products, almost all of which have blockbuster potential," targeting a commercial opportunity of more than $70 billion by the mid-2030s. The key question embedded in the current price, then, is not whether Merck looks expensive today, but whether those pipeline launches materialise on schedule — a risk underscored by the stock's history of drawdowns as large as 62% from prior peaks.

Keytruda generated $31.7 billion in 2025 revenue — 55% of Merck's total pharmaceutical sales — and faces U.S. patent expiration beginning in 2028, putting the company under pressure to secure replacement revenue before biosimilar competition erodes that base. CEO Robert Davis has signaled ongoing deal activity following recent acquisitions of Verona Pharma, Cidara Therapeutics, and Terns Pharmaceuticals ($6.7 billion, March 2026), stating publicly, "And we're not done." Large pharma broadly faces a projected $400–500 billion patent-expiration gap over the next decade, making M&A the primary lever to maintain revenue.

Retail traders are debating two speculative biotech targets: Sellas Life Sciences (SLS), whose WT1-targeting immunotherapy Galinpepimut-S is completing a Phase 3 trial in acute myeloid leukemia with broad multi-cancer application potential, and MoonLake Immunotherapeutics (MLTX), whose lead drug Sonelokimab is on track for a BLA submission by September 30 for hidradenitis suppurativa. T. Rowe Price CIO David Giroux named MoonLake among seven likely acquisition candidates and anticipates 50–100% acquisition premiums for biotech targets; a prior nonbinding Merck offer above $3 billion for MoonLake was reported last year. SLS has gained 155% since the Terns deal announcement, while MLTX message volume surged 760% in a week, reflecting heightened retail speculation rather than confirmed deal activity.